Vasogen Sees 2003 PMA For Vascular Disease Immune Modulation Therapy
This article was originally published in The Gray Sheet
Executive Summary
Vasogen plans to submit a premarket approval application in 2003 for its immune modulation therapy (IMT) for peripheral arterial disease (PAD)